Haleon’s organic sales growth was above market expectations last quarter, driven by strong demand for its oral health products.
The owners of brands including Sensodyne and Panadol reported organic revenue growth of 3.4% for the three months to 30 September, ahead of the 3.3% analysts expected in a company-compiled poll. Volumes were up 1.6% while prices grew 1.8%.
Oral health was the standout performer, with innovation driving strong market share gains for Sensodyne and Parodontax, according to CEO Brian McNamara.
Its vitamins, minerals and supplements division also delivered a good performance, supported by new launches for Centrum, Emergen-C, and Caltrate.
All regions delivered positive organic revenue growth with EMEA & LatAm up 5.3% and Asia-Pacific up 5.1%.
Emerging markets revenue was up 7.1% thanks to double-digit growth in India and mid-single-digit growth in China.
“EMEA & LatAm performed well, and we continued to grow market share in North America despite a challenging consumer environment,” McNamara said.
“We continue to deliver against our capital allocation priorities and so far this year have returned £1.1bn to shareholders, and during the quarter we completed the £500m share buyback programme we allocated to 2025.”
Haleon reiterated it is expecting 3.5% organic revenue growth for the full year, assuming a normal cold and flu season.
This outlook was lowered in July due to weak consumer sentiment in the US. It previously forecast between 4% and 6%.
No comments yet